ThromboGenics

08/09/2010

TIME: 14:54:34

LAST

17.64 €

OPEN

17.07 €

CHANGE

3.76 %

		I English I Nederlands
I 2010 I 2009 I 2008 I 2007 I 2006 I 2005 I 2004 I 2003

2009 I TOP

December 16, 2009

ThromboGenics completes patient enrolment of second Phase III trial of Microplasmin for the non-surgical treatment of eye disease... more »

December 11, 2009

ThromboGenics announces start of Phase II trial of Microplasmin for the treatment of Age-related Macular Degeneration (AMD)... more »

November 18, 2009

ThromboGenics and BioInvent win "Licensing Deal of the Year" at the Scrip Awards 2009... more »

November 17, 2009

ThromboGenics successfully completes private placement... more »

November 16, 2009

ThromboGenics announces private placement... more »

November 16, 2009

ThromboGenics and BioInvent complete Phase I patient trial of anti-PlGF cancer therapeutic TB-403... more »

AACR-NCI-EORTC Conference healthy volunteer results poster - AACR-NCI-EORTC Conference cancer patients results poster

November 4, 2009

ThromboGenics is today issuing a business update for the nine months period ended 30 September 2009... more »

October 28, 2009

ThromboGenics and BioInvent complete patient recruitment of phase II DVT prophylaxis study with Anti-Factor VIII

(TB-402)... more »

October 9, 2009

ThromboGenics raises 0.6 million Euro from the exercise of warrants... more »

October 5, 2009

ThromboGenics announces results from a Phase IIa trial evaluating microplasmin for the treatment of Diabetic Macular Edema... more »

September 24, 2009

ThromboGenics completes patient enrolment in US Phase III Trial of microplasmin for the non-surgical treatment of eye disease... more »

September 11, 2009

ThromboGenics is Shortlisted for “Biotech Company of the Year” and “Licensing Deal of the Year” at Scrip Awards 2009... more »

August 27, 2009
ThromboGenics NV announces business update and half year results 2009... more »

July 3, 2009

ThromboGenics and BioInvent start recruitment of second 100 patient cohort in Phase II study... more »

June 30, 2009

ThromboGenics promoted to the NEXT 150 Index... more »

June 25, 2009

ThromboGenics' Microplasmin phase III program progressing according to schedule... more »

May 14, 2009

ThromboGenics is today issuing a business update for the three month period ended 31 March 2009... more »

May 7, 2009

ThromboGenics raises 3.1 million Euro from the exercise of warrants... more »

March 12, 2009

ThromboGenics announces business update and 2008 full year results...more »

March 6, 2009

ThromboGenics completes patient enrolment for Phase II trial of Microplasmin for the treatment of Diabetic Macular Edema... more »

February 27, 2009

ThromboGenics awarded €3.2 million grant for the development of its anti-VPAC1 antibody for cancer chemotherapy induced thrombocytopenia... more »

February 23, 2009

ThromboGenics and BioInvent start Phase II trial of TB-402, a novel, long acting anticoagulant for Deep Vein Thrombosis (DVT) prophylaxis... more »

January 31, 2009

ThromboGenics’ proprietary cell lines introduced by GenOway in new stem cell production technology... more »

January 26, 2009

ThromboGenics and BioInvent receive technology transfer success fee from Roche for the novel anti-cancer antibody,

TB-403 (Anti-PIGF)... more »

January 9, 2009

ThromboGenics begins Phase III program with Microplasmin for the non-surgical treatment of back of the eye disease ... more »

2008 I TOP

November 14, 2008

ThromboGenics announces promising six month follow-up results from its Phase IIb trial of Microplasmin (MIVI III) for treatment of visual disorders... more »

November 06, 2008

Transparency declaration... more »

November 06, 2008

ThromboGenics is today issuing a business update for the nine months period ended 30 September 2008... more »

September 29, 2008

ThromboGenics announces promising results of MITI IV Phase II trial... more »

September 19, 2008

ThromboGenics are promoted to the Belgian Midcap Index... more »

August 28, 2008

ThromboGenics appoints Dr. Patrik De Haes as Chief Executive Officer... more »

August 28, 2008

ThromboGenics announces Half Year Results 2008... more »

July 30, 2008

ThromboGenics announces private investors acquire 8% stake in the company... more »

June 30, 2008

ThromboGenics announces positive results from its Phase IIb trial of Microplasmin in Vitrectomy (MIVI III)... more »

June 18, 2008

ThromboGenics and BioInvent announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibody... more »

A conference call took place on June 18th... replay »

June 3, 2008

ThromboGenics and BioInvent report positive Phase I results for anti-PlGF cancer therapeutic TB-403... more »

May 28, 2008

ThromboGenics announces the exercise of 172,629 warrants... more »

May 23, 2008

ThromboGenics presents further results of the Vitreomacular Traction Trial (MIVI IIT) at the Euretina Annual Meeting in Vienna... more »

May 13, 2008

ThromboGenics is today issuing a business update for the three month period ended 31 March 2008... more »

April 9, 2008

ThromboGenics announces that it has completed patient enrolment for its Phase II MITI IV study... more »

April 1, 2008

ThromboGenics announces that it has completed patient enrolment for its Phase IIb MIVI III trial... more »

March 31, 2008

ThromboGenics announces update of its financial calendar for 2008/2009... more »

March 18, 2008

ThromboGenics announces financial calendar for 2008/2009... more »

March13, 2008

ThromboGenics announces 2007 full year results... more »

January 18, 2008

ThromboGenics and BioInvent receive approval to begin clinical trials of TB-403 for the treatment of cancer... more »

2007 I TOP

December 11, 2007

ThromboGenics presents results of Phase I Trial of TB-402 at ASH... more »

ASH presentation »

December 4, 2007

ThromboGenics presents results of vitreomacular traction trial at ASRS... more »

Nov 14, 2007

ThromboGenics begins preclinical development of Anti-VPAC antibody for thrombocytopenia... more »

link to Blood publication »

Nov 2, 2007

ThromboGenics and BioInvent announce publication of exciting data on a novel class of angiogenesis inhibitors in Cell... more »

anti-PlGF mechanism of action »

Oct 4, 2007

ThromboGenics and Rhein Minapharm announce agreement for next-generation thrombolytic agent... more »

Sep 21, 2007

ThromboGenics completes enrolment of patients for the vitreomacular traction trial... more »

Sep 20, 2007

ThromboGenics announces exercise of 1.147.825 warrants... more »

Sep 7, 2007

ThromboGenics and BioInvent announce successful completion of phase I trial with TB-402... more »

Sep 4, 2007

ThromboGenics announces successful completion of tech transfer to Bharat Biotech... more »

Aug 24, 2007

ThromboGenics announces interim results... more »

July 5, 2007

ThromboGenics completes absorbtion of its subsidiary Thromb-X NV... more »

May 23, 2007

ThromboGenics plans to absorb its subsidiary Thromb-X NV... more »

Merger proposal

May 9, 2007

ThromboGenics succesfully completes private offering raising 23.9 million euro... more »

May 9, 2007

ThromboGenics engaged in private offering... more »

May 2, 2007

ThromboGenics announces progress on pre-clinical and clinical programs... more »

April 16, 2007

ThromboGenics announces license agreement with Millipore for commercialization of stem cell medium technology... more »

March 27, 2007

GO Capital becomes major shareholder in ThromboGenics... more »

March 2, 2007

Prof. Désiré Collen, Chairman and CEO of ThromboGenics, awarded 2007 Harvard Leadership Prize... more »

February 15, 2007

ThromboGenics announces business update and Half Year Results... more »

February 12, 2007

ThromboGenics and BioInvent receive approval to begin clinical trials for anticoagulant TB-402... more »

February 5, 2007

ThromboGenics strengthens management team with COO and Patent Counsel... more »

January 15, 2007

ThromboGenics and Geymonat awarded Euro 2 Million EU Grant for VASOPLUS Pro-Angiogenesis Programme... more »

January 8, 2007

ThromboGenics initiates Phase IIb U.S. clinical trial of Microplasmin in vitrectomy... more »

2006 I TOP

December 28, 2006

ThromboGenics and BioInvent awarded Euro 2 Million EU Grant for ANGIOSTOP Anti-Angiogenesis Programme... more »

December 6, 2006

ThromboGenics announces license agreement with Bharat Biotech (India) for novel thrombolytic agent... more »

November 13, 2006

ThromboGenics announces IND clearance from FDA for microplasmin intraocular injection... more »

October 20 , 2006

ThromboGenics announces the first presentation of the results of the MIVI-I Phase IIa trial... more »

October 19 , 2006

Roche Diagnostics, ThromboGenics and Geymonat announced the signing of a license agreement... more »

September 26, 2006

ThromboGenics announces an update of its development plans for microplasmin in the field of peripheral occlusive disease... more »

September 22, 2006

ThromboGenics announces the initiation of a Phase IIa clinical trial to evaluate microplasmin for the intra-arterial treatment of stroke... more »

September 13, 2006

ThromboGenics announces that it has completed the enrolment and treatment of all 60 patients to be included in its MIVI-I trial... more »

August 30, 2006

ThromboGenics announces its Financial Calendar for 2006/2007... more »

August 16, 2006

ThromboGenics Appoints Chris Buyse as New Chief Financial Officer and Director... more »

July 31, 2006

ThromboGenics announces that the Over-Allotment Option has been fully exercised at the offer price, in accordance with its prospectus... more »

July 6, 2006

ThromboGenics raises the envisaged €35 million in its IPO and additionally €3.5 million in over-allotment shares will be allocated... more »

2005 I TOP

January 18, 2005

ThromboGenics Announces The Initiation of Phase II Trial of Microplasmin... more »

2004 I TOP

December 17, 2004

ThromboGenics and BioInvent Add New Anti-Angiogenesis Program to Collaboration... more »

September 27, 2004

ThromboGenics and BioInvent Strike Alliance to Jointly Develop Antibody-Based Therapeutics... more »

April 1, 2004

ThromboGenics Granted FDA Orphan Drug Designation for Microplasmin Use in Pediatric Eye Surgery... more »

March 10, 2004

ThromboGenics and NuVue Technologies to Collaborate on Development of Plasmin-Based Drugs for Visual Disorders... more »

February 25, 2004

ThromboGenics and Geymonat Announce Collaboration for Development of PlGF (Placental Growth Factor) in Angiogenesis... more »

2003 I TOP

July 10, 2003

New Study In July 1, 2003 Nature Medicine Highlights Role Of PlGF (Placental Growth Factor) in Angiogenesis... more »

October 15, 2003

ThromboGenics Reports New Embryonic Stem Cell Medium for Derivation of Non-Permissive Strains... more »

Last update: April 15, 2010

Inspired by Echo